2 / 5
Euro Vaccines 2018 & Antibiotics 2018
June 14-16, 2018
Page 36
conference
series
.com
JOINT EVENT
31
st
Euro Global Summit and Expo on
Vaccines & Vaccination
4
th
World Congress and Exhibition on
Antibiotics and Antibiotic Resistance
&
June 14-16, 2018 Barcelona, Spain
Volume 9
Gabriel Kristian Pedersen, J Vaccines Vaccin 2018, Volume 9
DOI: 10.4172/2157-7560-C2-064
Targeted delivery in rational vaccine design
N
ovel vaccine strategies include the so-called subunit vaccines, which encompass only the part of the pathogen to which immune
recognition results in protection.The high purity of these vaccines makes adverse events less likely, but it alsomakes the vaccines
less immunogenic and therefore potentially less effective. Vaccine adjuvants that increase and modulate the immunogenicity of the
vaccine are therefore added to solve this problem. Besides aluminum salts, which have been used in vaccines for 90 years, a number
of novel vaccine adjuvants include delivery systems like liposomes and emulsions have been included in licensed vaccines over the
last 30 years. However trial-and-error has been the explorative approach of choice, for the design of novel vaccine adjuvants due to
major gaps in the knowledge about immunological activation processes. Increasing insight into immunological mechanisms and
how to manipulate them has replaced empirical with rational design of adjuvants, leading to vaccine adjuvants with increased and
customized immunogenicity profiles without compromising vaccine safety. I will present an overview of where vaccine adjuvant
research is today. I will furthermore show an example where the newest knowledge in innate immunology enables the rational design
of a novel CTL inducing vaccine adjuvant.
Biography
Gabriel Pedersen is an immunologist and head of section for the Adjuvant Research group at the Center for Vaccine research, Statens Serum Institut, Copenhagen.
Gabriel did his PhD at University of Bergen, Norway, focusing on pandemic influenza vaccines, before moving to Karolinska Institutet, Sweden, to do a postdoc in B cell
biology, with particular focus on innate-like B cells. Since 2016, he has focused on adjuvant research on SSIs novel pipeline of adjuvants, particularly focusing on liposome
and emulsion-based adjuvant and delivery systems.
GAKP@ssi.dkGabriel Kristian Pedersen
Statens Serum Institut, Denmark
Journal of Vaccines & Vaccination
ISSN: 2157-7560